Savara Inc.
NASDAQ:SVRABiotechnology
+$0.03 today
- Market cap
- $1.04B
- Beta
- 0.27
- P/E (TTM)
- -10.6
- EPS (TTM)
- -$0.51
Volume 5.51M
Average 1.53M
SVRA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Savara Inc.NASDAQ: SVRA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$37.22M, compared with -$27.62M a year earlier. Trailing-twelve-month EBITDA was -$129.27M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -16.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$37.22M-15.6% QoQ
- Last fiscal yearDec 2025
- -$118.59M-16.0% YoY
- LTMMar 2026
- -$129.27M-25.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -34.7% | +100.0% | +134.7 pp |
| 1 year | -16.0% | +100.0% | +116.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (118.59M) USD
- Year-over-year change
- -16.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (118.59M) | -16.0% |
| FY2024 | 2024-12-31 | (102.27M) | -72.9% |
| FY2023 | 2023-12-31 | (59.13M) | -55.6% |
| FY2022 | 2022-12-31 | (38.01M) | +6.1% |
| FY2021 | 2021-12-31 | (40.5M) | — |
EBITDA vs competitors
How SVRA compares with its peers on the latest reported figures
- SVRA's LTM Mar 2026 EBITDA of -$129.27M is the lowest of the 2 companies compared; the peer median is $142.5M.
- Its year-over-year change of -25.5% is the lowest of 2, against a peer median of +440.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.5M | +440.4% | — | 129.8% | |
| LTM Mar 2026 | -$129.27M | -25.5% | — | — | |
APMDApnimed, Inc. | — | — | — | — | — |
| Peer median (excluding SVRA) | $142.5M | +440.4% | — | 129.8% | |
Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 28.99M | 27.88M | 44.26M | 78.03M | 245K |
| Gross Profit | (28.99M) | (27.88M) | (44.26M) | (78.03M) | (245K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 28.99M | 27.88M | 44.26M | 78.03M | 81.4M |
| Selling, General & Admin | 12.35M | 10.93M | 15.67M | 25.04M | 42.06M |
| Operating Expenses | 12.49M | 10.96M | 15.75M | 25.17M | 123.3M |
| Depreciation & Amortization | 136K | 31K | 77K | 130K | 245K |
| EBITDA | (40.5M) | (38.01M) | (59.13M) | (102.27M) | (118.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (41.48M) | (38.84M) | (60.01M) | (103.2M) | (123.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.28K | 88 | 4.44M | 6.47M | 4.16M |
| Interest Expense | 2.28M | 88K | 0 | 0 | 0 |
| Other Income / Expenses | (1.54M) | 689K | 5.31M | 7.32M | 4.71M |
| Income Before Tax | (43.01M) | (38.15M) | (54.7M) | (95.88M) | (118.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.01M) | (38.15M) | (54.7M) | (95.88M) | (118.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.32) | (0.25) | (0.33) | (0.48) | (0.53) |
| EPS (Diluted) | (0.32) | (0.25) | (0.33) | (0.48) | (0.53) |
| Weighted Avg Shares | 133.92M | 152.77M | 165.2M | 198.19M | 222.39M |
| Weighted Avg Shares (Diluted) | 133.92M | 152.77M | 165.2M | 198.19M | 222.39M |
Savara Inc.
NASDAQ:SVRA
Intrinsic Alpha fair value
Locked
Current Price
$4.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.